Dexamethasone suppression tests in patients with obsessive-compulsive disorder. 1985

J A Lieberman, and J M Kane, and S Sarantakos, and K Cole, and A Howard, and M Borenstein, and H Novacenko, and J Puig-Antich

Obsessive-compulsive disorder and major depressive disorder are associated by several lines of evidence. To explore the possible relationship between the two disorders, the authors administered 1-mg dexamethasone suppression tests to 18 patients with obsessive-compulsive disorder and 51 patients with major depressive disorder. None of the obsessive-compulsive patients were classified as nonsuppressors on the basis of a 4:00 p.m. serum cortisol level, whereas 37% of the depressed patients were nonsuppressors. The mean cortisol levels of the two groups differed significantly. Factors that may influence hypothalamic-pituitary-adrenal function, such as age, depressive symptoms, and severity of illness, are discussed in light of these results.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009771 Obsessive-Compulsive Disorder An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension. Anankastic Personality,Neurosis, Obsessive-Compulsive,Anankastic Personalities,Disorder, Obsessive-Compulsive,Disorders, Obsessive-Compulsive,Neuroses, Obsessive-Compulsive,Neurosis, Obsessive Compulsive,Obsessive Compulsive Disorder,Obsessive-Compulsive Disorders,Obsessive-Compulsive Neuroses,Obsessive-Compulsive Neurosis,Personalities, Anankastic,Personality, Anankastic
D011569 Psychiatric Status Rating Scales Standardized procedures utilizing rating scales or interview schedules carried out by health personnel for evaluating the degree of mental illness. Factor Construct Rating Scales (FCRS),Katz Adjustment Scales,Lorr's Inpatient Multidimensional Psychiatric Rating Scale,Wittenborn Scales,Edinburgh Postnatal Depression Scale,Mini International Neuropsychiatric Interview
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006854 Hydrocortisone The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions. Cortef,Cortisol,Pregn-4-ene-3,20-dione, 11,17,21-trihydroxy-, (11beta)-,11-Epicortisol,Cortifair,Cortril,Epicortisol,Hydrocortisone, (11 alpha)-Isomer,Hydrocortisone, (9 beta,10 alpha,11 alpha)-Isomer,11 Epicortisol

Related Publications

J A Lieberman, and J M Kane, and S Sarantakos, and K Cole, and A Howard, and M Borenstein, and H Novacenko, and J Puig-Antich
April 1982, Psychiatry research,
J A Lieberman, and J M Kane, and S Sarantakos, and K Cole, and A Howard, and M Borenstein, and H Novacenko, and J Puig-Antich
March 1986, The British journal of psychiatry : the journal of mental science,
J A Lieberman, and J M Kane, and S Sarantakos, and K Cole, and A Howard, and M Borenstein, and H Novacenko, and J Puig-Antich
June 1987, Journal of clinical psychopharmacology,
J A Lieberman, and J M Kane, and S Sarantakos, and K Cole, and A Howard, and M Borenstein, and H Novacenko, and J Puig-Antich
January 1990, Neuropsychobiology,
J A Lieberman, and J M Kane, and S Sarantakos, and K Cole, and A Howard, and M Borenstein, and H Novacenko, and J Puig-Antich
June 2007, Psychiatry research,
J A Lieberman, and J M Kane, and S Sarantakos, and K Cole, and A Howard, and M Borenstein, and H Novacenko, and J Puig-Antich
November 2002, Behaviour research and therapy,
J A Lieberman, and J M Kane, and S Sarantakos, and K Cole, and A Howard, and M Borenstein, and H Novacenko, and J Puig-Antich
April 1987, Indian journal of psychiatry,
J A Lieberman, and J M Kane, and S Sarantakos, and K Cole, and A Howard, and M Borenstein, and H Novacenko, and J Puig-Antich
October 1984, Psychiatry research,
J A Lieberman, and J M Kane, and S Sarantakos, and K Cole, and A Howard, and M Borenstein, and H Novacenko, and J Puig-Antich
April 2005, Journal of clinical psychology,
J A Lieberman, and J M Kane, and S Sarantakos, and K Cole, and A Howard, and M Borenstein, and H Novacenko, and J Puig-Antich
August 2009, Progress in neuro-psychopharmacology & biological psychiatry,
Copied contents to your clipboard!